Tools that help reduce the number of surgical biopsies performed on benign lesions have the potential to improve patient care. The pigmented lesion assay (PLA) is a noninvasive tool validated against histopathology that helps rule out melanoma and the need for surgical biopsies of atypical pigmented skin lesions. Genetic information is collected using adhesive patches and the expression of two genes, LINC and PRAME, is measured. By using genetic material collected noninvasively and to further validate the PLA, somatic hotspot mutations in genes known to be drivers of early melanoma development (BRAF other than V600E, NRAS, and the TERT promoter) can also be identified. The frequency of these hotspot mutations in samples of early melanoma was 77%, which is higher than the 14% found in nonmelanoma samples (P < 0.0001). TERT promoter mutations were the most prevalent mutation type in PLA-positive melanomas; 82% of PLA-negative lesions had no mutations, and 97% of histopathologically confirmed melanomas were PLA and/or mutation positive (cohort 1, n ¼ 103). Mutation frequencies were similar in prospectively collected real-world PLA samples (cohort 2, n ¼ 519), in which 88% of PLA-negative samples had no mutations. Combining gene expression and mutation analyses enhances the ability to noninvasively detect early cutaneous melanoma.
INTRODUCTION
Currently, cutaneous melanoma is typically diagnosed based on histologic examination of lesions identified as suspicious based on clinical appearance (Bichakjian et al., 2011; High, 2017) . As our understanding of the genetic basis of melanoma unfolds, the assumption is that genetic mutations and other early changes responsible for tumor promotion will result in morphologic changes that pathologists describe and use to make the histopathologic diagnoses upon which clinical decision making is currently based. Histology can thus be seen as a surrogate marker of the mutational burden and genetic changes of a melanocytic lesion, and there are several disadvantages to this more indirect approach. First, to acquire tissue for evaluation, a surgical biopsy must be performed, which carries the risk of scarring and infection. Second, about 90% of about 3,000,000 biopsies performed annually in the United States to rule out melanoma are found to be benign or low-risk lesions and thus are surgically biopsied without clear benefit to the patient (Lott et al., 2018; Nufer et al., 2018) . Third, histology is subjective, and consensus agreement among pathologists is lower than expected by many, as corroborated by a recent landmark study analyzing performance data from 10 US states (Elmore et al., 2017) . The calculated sensitivity of histopathology for early melanomas (Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis [MPATH-Dx] class III and IV, melanoma in situ and early invasive pT1a melanoma cases), based on data by Elmore et al. (2017) was 65%. These numbers highlight the fact that the current criterion standard leaves room for improvement (Elmore et al., 2017) . Based on this and other key studies, the negative predictive value for the current surgical biopsy pathway is around 83%, reflecting the fact that in addition to the low specificity of the current approach, there is also a 17% probability of missing melanomas (Malvehy et al., 2014; Elmore et al., 2017) .
The recently described pigmented lesion assay (PLA), is a molecular tool for clinicians that uses gene expression profiling to aid in making biopsy decisions to rule out melanoma (Childs, 2018; Ferris et al., 2017 Ferris et al., , 2018 Gerami et al., 2017; Hornberger and Siegel, 2018; Rivers et al., 2018; Yao et al., 2016 Yao et al., , 2017 . Using adhesive patches for noninvasive sample collection, the PLA analyzes the expression of two genes, LINC and PRAME, both of which are often increased in melanoma (Gerami et al., 2017; Yao et al., 2017) . PRAME is a cancer biomarker used in two other commercial melanoma tests, and LINC is part of a new class of regulatory RNAs that play an important role in cancer biology (Clarke, et al., 2015; Gerami et al., 2017; Haqq et al., 2005) .
The performance metrics of the PLA were validated against histopathologic consensus reads (by three dermatopathologists specializing in pigmented lesions) (Gerami et al., 2017) . Compared with the current standard of visual assessment followed by histopathology, the PLA has a lower false negative rate (9% vs. 16%), a higher negative predictive value (99% vs. 83%), and a higher specificity (<32% vs. >69%) (Ferris et al., 2017 (Ferris et al., , 2018 .
Somatic mutations in BRAF (other than V600E), NRAS, and the TERT promoter have recently been characterized as key drivers of early stage melanoma. The biology of early cutaneous melanoma is generally driven by initial UV damage events that lead to somatic hotspot mutations in these relatively small numbers of key target genes that alter gene expression and ultimately result in functional changes and morphological changes of melanocytic lesions (Chiba et al., 2017; Horn et al., 2013; Huang et al., 2013; Liu et al., 2016; Mar et al., 2013; Menzies et al., 2012; Shain et al., 2015 Shain et al., , 2016 Shay, 2017; Tsao et al., 2012) . These early hotspot driver mutations in BRAF, NRAS, and especially TERT, not only correlate with adverse histopathologic criteria, but are found in early and persist in late stage disease, identifying risk of aggressive tumor behavior with metastasis and poor prognosis (Griewank et al., 2014; Liu et al., 2016; Nagore et al., 2016; Poynter et al., 2006; Prior et al., 2012; Roh et al., 2017; Shain et al., 2016; Vinagre et al., 2013; Yeh et al., 2013) .
We recently optimized the ability to reliably extract both DNA and RNA from adhesive patch skin samples, which made it possible to noninvasively analyze pigmented lesions suspicious for melanoma, not only for gene expression via PLA, but also for the presence of somatic mutations. In this study, we correlated the presence of hotspot driver mutations described in early melanoma and lesions transitioning toward early melanoma with PLA results. Our objective was to determine if histology and expression of LINC and PRAME, the roles of which in melanoma progression are less well characterized, correlate with the presence of somatic mutations in the TERT promoter, in NRAS, and in BRAF (other than V600E, also frequently found in nevi), allowing mutations to serve as an additional PLA validation platform. We also attempted to determine if a combined strategy based on gene expression and mutation analyses affects the sensitivity and specificity of the PLA.
RESULTS
The study designs for patient cohorts 1 and 2 are summarized in Figure 1 . Cohort 1 (n ¼ 103, archival) consisted of patients for whom both PLA and histopathology results were obtained, and cohort 2 (n ¼ 519, prospective) consisted of patients with real-world routine-use PLA (histopathology not available). We identified somatic mutations in three genes (BRAF other than V600E, NRAS, and the TERT promoter) known to be drivers of early melanoma development in a total of 622 PLA-tested pigmented lesions clinically suspicious for melanoma. Table 1 summarizes cohort 1 results of histopathologic consensus diagnoses, gene expression (PLA), and mutation analyses. Of 103 cohort 1 patients, 30 had melanomas (six melanomas in situ and 24 invasive melanomas with a median tumor thickness of 0.58 mm), and 73 had nonmelanoma lesions, including 61 nevi (46 atypical and 15 conventional nevi) and 12 lesions with nonmelanocytic consensus diagnoses (two seborrheic keratoses, eight solar lentigines, and two squamous cell carcinomas). The PLA result was positive (LINC and/or PRAME gene expression detected) in 28 (93%) of 30 patients, with a histopathologic consensus diagnosis of melanoma in 31 (42%) of 73 nonmelanoma patients. Mutation analysis showed hotspot driver mutations (BRAF other than V600E, NRAS, or TERT promoter mutations) in 23 (77%) of the 30 melanoma patients but only in 10 (14%) of the 73 nonmelanoma patients. The frequency of the assessed early hotspot driver mutations in histopathologically confirmed melanomas (77%, 23/30) is statistically higher than the frequency in nonmelanomas (14%, 10/73; P < 0.0001). Ninety-seven percent of patients (29/30) with a histopathologic consensus diagnosis of melanoma were either PLA gene expression or mutation positive, and 48% (35/73) of nonmelanomas were negative for expression of LINC, PRAME, and driver mutations, highlighting the allure of an approach that looks at both RNA and DNA risk factors in a single noninvasively obtained sample. In addition, Table 1 shows that TERT promoter mutations were the most prevalent mutation type both in melanomas confirmed by histopathologic consensus diagnosis (73%, 22/30) and in PLA-positive melanomas (79%, 22/28). The TERT promoter mutations observed most often were e124G>A and e146G>A mutations (each present in 11 patients, and single patients also harbored e126G>A, e132G>A, and e138G>A mutations). BRAF V600E mutations were present at similar frequencies in melanoma and nonmelanoma samples (in 10% [3/30] and 8% [6/73] patients, respectively). Conversely, BRAF V600K mutations (6%, 2/30) and NRAS G61R and K5E (10%, 3/30) mutations were found in melanomas only. Thirty-eight percent (9/24) of invasive and 17% of (1/6) in situ melanomas harbored multiple hotspot mutations. Table 2 provides details on two PLA-negative patients with histopathologically diagnosed melanomas. One of the patients harbored two TERT mutations, and the other patient showed no assessed molecular risk factors. Table 3 expands the data presented and correlates histopathologic diagnoses with mutation analyses and PLA results (double positive with LINC and PRAME detected and single positive with either LINC or PRAME gene expression detected). Ninety-three percent (28/30) of all melanomas confirmed by histopathologic consensus diagnoses were PLA positive (95% [23/24] invasive and 83% [5/6] in situ melanomas). PLA positive results were observed in 42% (31/73) of nonmelanoma patients in cohort 1. The highest percentage of the PLA-positive nonmelanoma samples (68%, 15/22)) occurred in nevi read as severely dysplastic by at least one of the three consensus panel dermatopathologists. The presence of hotspot driver mutations other than BRAF V600E followed the same pattern as PLA gene expression results. These hotspot driver mutations were detected in 83% (20/24) invasive and 50% (3/6) in situ melanomas but only in 14% of nonmelanoma patients (11% [5/46] in atypical nevi, 13% [2/15] in conventional nevi, and 17% [2/12] in nonmelanocytic lesions). Figure 2 shows how the presence of different hotspot driver mutations (excluding BRAF V600E), gene expression consistent with melanoma (LINC and/or PRAME detected), and histopathology (consensus diagnosis established by three expert dermatopathologists) correlate. Overall, the presence of hotspot driver mutations overlaps with positive gene expression and histopathology with 79% (22/28) of PLA-positive melanoma patients harboring at least one driver mutation, whereas only 10% (3/31) of PLA-positive nonmelanoma patients harbored hotspot mutations. The frequency of hotspot driver mutations other than BRAF V600E in melanomas was the highest in lesions located on extremities (93%, 13/14) followed by lesions on the face (67%, 6/9) and the trunk (57%, 4/7). The same pattern was maintained for patients with nonmelanoma consensus diagnoses, of whom 33% (6/18) with lesions on extremities, 23% (3/13) with lesions on the face, and 2% (1/42) with lesions on the trunk had detectable mutations in BRAF (other than V600E), NRAS, or the TERT promoter.
After establishing in well-annotated cohort 1 samples that the hotspot driver mutations in BRAF other than V600E, NRAS, and the TERT promoter investigated here and known to arise during the development of early-stage melanoma are present in about 80% of PLA-positive adhesive patch samples diagnosed histopathologically as melanomas but are absent in more than 80% of nonmelanoma samples, we studied the presence or absence of these mutations in more than 500 routine-use PLA samples ( Figure 1 summarizes the study design). A total of 519 prospectively collected real-world PLA samples from cohort 2 (387 PLA-negative and 132-PLA positive samples) were analyzed for these same mutations, and a similar difference in the frequency of hotspot driver mutations was found (Table 4 ). Eighty-eight percent (342/387) of real-world PLA-negative samples were also negative for any of these melanoma-related mutations, similar to the 82% (36/44) in cohort 1 (Figure 3 ). The mutation frequencies in cohort 1 and cohort 2 were not statistically different.
DISCUSSION
We showed that expression of LINC and PRAME determined noninvasively via PLA is highly correlated with the presence of somatic mutations in three genes (BRAF non-V600E, NRAS, and TERT) known to be important in melanoma development and progression. Mutations detected by PLA are highly correlated to those found in surgical biopsy tissue blocks, showing that both RNA expression and somatic mutations can be detected noninvasively using the PLA. These findings are important for two reasons. First, assessing the genetic profile of a pigmented lesion provides insight into its malignant potential with a biologic basis that is consistent with the known role of these genes in melanoma progression and with an objectivity that histology alone cannot provide. Second, by analyzing both gene expression and somatic mutations, the sensitivity of noninvasive PLA testing further improves to a level at which 97% of melanomas can be identified based on a reference standard that uses consensus diagnoses from three expert dermatopathologists. These findings help further validate the importance of LINC and PRAME genes in melanoma and expand the depth of molecular risk factor analysis in noninvasively obtained samples to help clinicians make more informed biopsy decisions and limit the number of benign biopsies performed. These findings were further evaluated in a large, real-world, US dermatology office cohort of 519 patients with lesions clinically suspicious for melanoma, corroborating the differences in mutation frequency between PLA-positive and PLA-negative results.
In addition to providing an option for situations in which a surgical biopsy is undesirable, there are other advantages to using molecular risk factor data to aid in diagnosing melanoma. Although melanoma has traditionally been diagnosed based on histology, several studies have shown significant intrarater and interrater variation in the classification of melanocytic lesions. Figure 1 . Study design and patient information. Cohort 1 (n ¼ 103) included patients with fully annotated archival PLA results with histopathology based on consensus diagnosis by three dermatopathology experts. Cohort 2 (n ¼ 519) included US patients with prospectively collected, real-world routine-use PLA. PLA, pigmented lesion assay.
In many cases, these variations are not subtle grading of atypia but would result in differential patient treatment plans (Elmore et al., 2017; Malvehy et al., 2014) . The evolution of melanoma is now better understood, and adding mutations and gene expression changes present in early stage melanoma to an improved toolbox may lead to a more rational and accurate way to diagnose melanoma at its earliest stages when morphological alterations may not yet be present.
Our findings are in agreement with those of others who have studied mutations in melanoma and precursor nevi. The progression of melanocytic skin lesions is generally initiated by BRAF and NRAS mutations known to activate the MAPK pathway, followed by telomerase activation and disruption of G1-S checkpoints (Chiba et al., 2017; Shain et al., 2015 Shain et al., , 2016 Shay, 2017; Tsao et al., 2012) . Because somatic mutations in melanoma are frequently consequences of UV damage events and early occurrences in the establishment of melanoma, this study confirms PLA's ability to identify at-risk lesions early and may also allow the identification of a subset of early disease with potentially indeterminate morphological findings described as intermediate neoplasms (Shain et al., 2015 (Shain et al., , 2016 . In addition, these hotspot driver mutations have prognostic implications. In our study, invasive melanomas carried multiple hotspot mutations over twice as often as in situ melanomas; multiple mutations have also been reported to be associated with adverse histopathology (higher mitotic index and tumor thickness), disease progression, and worse prognosis by others (Nagore et al., 2016) . Although TERT promoter mutations, among other mutations, have also been described in lesions other than melanoma (Heidenreich et al., 2017) , they are independently associated with poor overall survival in patients with nonacral melanomas (median survival ¼ 80 months vs. 291 months for wild type, P ¼ 0.006), and the coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with clinicopathological features of tumor aggressiveness (Griewank et al., 2014; Macerola et al., 2015) . Additionally, TERT promoter mutations in combination with BRAF/NRAS mutations can be used to identify patients at risk for aggressive disease (Nagore et al., 2016) . As our understanding improves further, the type of observed hotspot mutations may carry additional prognostic information.
Not all TERT promoter mutations, the mutation type observed in 79% of melanomas confirmed by histopathologic consensus diagnosis, may be created equal. Borah et al. (2015) found TERT promoter mutations at position e124 in most of their urothelial cancer cell lines studies, and this mutation may confer tumor aggressiveness and facilitate the establishment of cell lines. Although further studies are needed to elucidate the roles that different TERT promoter mutations may play in the progression of melanocytic lesions, it is of interest to note that e124 mutations were the mutation type most often observed in melanomas positive for both LINC and PRAME.
Our growing understanding of the genetic evolution of cutaneous melanomas also creates opportunities for improving the PLA assay. In this study, 97% of histopathologically confirmed melanomas were PLA and/or mutation positive, with a specificity of 48%, highlighting the potential of combined mutation and gene expression analyses to improve the accuracy of diagnosing melanoma noninvasively. Also, although most other image-based diagnostic aids frequently misclassify seborrheic keratoses as higher grade melanocytic lesions, we showed that using LINC and PRAME expression analysis accurately classified all seborrheic keratoses as benign (Malvehy et al., 2014) . This is important, because these lesions are frequently the cause of referrals to dermatology specialists by primary care providers, and providing them with such a tool could reduce avoidable referrals.
Based on the findings presented here and a growing body of evidence form other groups (Chiba et al., 2017; Griewank et al., 2014; Macerola et al., 2015; Nagore et al., 2016; Shain et al., 2015 Shain et al., , 2016 Shay, 2017; Tsao et al., 2012) , we believe that the assessment of early stage melanoma should ultimately shift away from morphologic assessment of disease risk to a molecular assessment of disease risk based on gene expression and mutations. We present data showing that this information can be obtained noninvasively and with high sensitivity and specificity.
MATERIALS AND METHODS

Study subjects and sample collection
This study was conducted in accordance with the Declaration of Helsinki principles and was approved by the Western-Copernicus Group (Santee, CA) independent review board. Figure 1 outlines the study design and summarizes key patient information. The study included a total of 622 epidermal skin samples from two patient cohorts with pigmented skin lesions clinically suspicious for melanoma and collected noninvasively from the patients by using an adhesive patch sample collection kit according to package insert instructions (DermTech, La Jolla, CA). Written informed patient consent was obtained for cohort 1 as required by the ( Overall,11/12 (92%) of the nonmelanocytic lesions studied were PLA negative (a single solar lentigo showed detectable levels of LINC gene expression). Two of 11 of the PLA-negative samples, nonmelanocytic by histopathology (one solar lentigo and one seborrheic keratosis), showed TERT mutations. (n [ 103) .
Samples with Hotspot Mutations
Differences between melanoma and nonmelanoma groups were highly statistically significant (P < 0.0001). Tables 1e3 provide further details on this visual overview. PLA, pigmented lesion assay.
independent review board. The need for written informed consent was waived by the independent review board for cohort 2 realworld use subjects.
Nucleic acid extraction and quantification
Adhesive patches with pigmented lesion epidermal skin samples were macrodissected via CO 2 laser (GCC, New Taipei City, Taiwan) to separate pigmented lesion material from surrounding normal skin tissue. Cells from the macrodissected area were lysed in a modified lysis buffer obtained from Norgen (Thorold, Ontario, Canada), and both RNA and DNA were co-extracted from the cell lysate using silica-coated magnetic beads on a KingFisher Duo Primer System (Thermo Fisher Scientific, Waltham, MA). Total human RNA and human genomic DNA (gDNA) in bead extraction eluents were quantified by quantitative real-time reverse transcriptaseePCR (rt-qPCR) (for RNA) and quantitative PCR (qPCR) (for gDNA) on an ABI7900 PCR system (Life Technologies, Carlsbad, CA), with qScript cDNA SuperMix (Quanta Biosciences, Beverly, MA, for RNA reverse transcription to cDNA) and Takyon Rox Probe Mastermix UNG (Eurogentec, Liege, Belgium, for qPCR on cDNA and gDNA) following the manufacturers' instructions. Total human RNA in bead eluents was quantified by using a human b-actin (ACTB) gene transcript (mRNA) as a quantification marker and a TaqMan gene expression assay (Hs01060665_g1, probe spans exons), and human gDNA in the same bead eluents was quantified by using the same ACTB gene as a quantification marker but a separate TaqMan ACTB gene copy number assay (Hs03023880_g1, primers and probe within the same exon). Both TaqMan ACTB assays (one for RNA and one for gDNA quantification) were purchased from Life Technologies (Waltham, MA) and used on an ABI 7900 PCR (Life Technologies) system, following the manufacturer's instructions. Details of the process have been reported previously (Gerami et al., 2017; Yao et al., 2016 Yao et al., , 2017 .
Target gene expression
After quantification, a normalized quantity of total human RNA from the bead eluents was used for gene expression analysis of the two melanoma-associated genes, LINC and PRAME, through quantitative real-time reverse transcriptaseePCR on an ABI 7900 PCR system (Life Technologies). In brief, total RNA from the bead eluent was first reverse transcribed to cDNA, which was then used in two biplex qPCR reactions, one containing TaqMan probes for LINC (Hs00332749_m1, probe spans exons) and ACTB (Hs01060665_g1, probe spans exons, where ACTB serves as a control) and one containing TaqMan probes for PRAME (Hs01022301_m1, probe spans exons) and PPIA (Hs04194521_s1, probe spans exons, where PPIA serves as another control). Each biplex qPCR reaction received an amount of the cDNA equivalent to 3 pg of total human RNA in the bead eluents (normalized through the ACTB gene expression assay) and was run in duplicate. All TaqMan probes were purchased from Life Technologies. Any qPCR reactions that produced a detectable amplification (or measurable Ct count) of LINC, PRAME, or both LINC and PRAME were considered PLA detection positive and consistent with a gene expression pattern observed in melanoma.
Target gene mutation analysis
Sanger sequencing was used to detect gene mutations in human gDNA from the same bead eluents that were tested on LINC and PRAME gene Figure 3 . Comparison of hotspot driver mutations in PLA-negative samples of cohort 1 and cohort 2. PLA-negative samples were assessed for the absence of BRAF (non-V600E), NRAS, and TERT promoter hotspot mutations. There were no statistically significant differences between cohort 1 and cohort 2. Details on the mutation status of PLA-positive cohort 1 and cohort 2 samples are provided in Table 4 . PLA, pigmented lesion assay. expression with PLA. Bead eluents contain both human total RNA and human gDNA from the skin samples collected with the adhesive patch sampling platform described. PCR amplicons were generated from each gDNA sample from five gene regions known to accumulate UV damage-induced somatic mutations of the three genes, BRAF, NRAS, and TERT promoter. These included two amplicons for the two BRAF gene exons that cover the hotspot mutations at the 600th and 469th amino acids; two amplicons for the two NRAS gene exons that cover hotspot mutations at the 12th, 13th, and 61st amino acids; and one amplicon from the promoter region of TERT that covers described key hotspot mutations at e124G>A, e124/125GG>AA, e138/ 139GG>AA, e146G>A, and e149G>A. The four amplicons from BRAF and NRAS were co-amplified in a multiplex PCR reaction, and the amplicon on the TERT promoter region was amplified in a monoplex PCR reaction. Both PCR reactions were run in 25 mL final volume of 1Â AccuStart II GelTrack PCR SuperMix from Quanta Biosciences (Gaithersburg, MD) that contained 200 nmol/L of each primer (forward and reverse for each exon) and 100 pg of human gDNA from the bead eluent, with the exception of the TERT monoplex PCR, which also contained 3% DMSO. The multiplex PCR reactions (for BRAF and NRAS) were cycled 40 times at 94 C for 30 seconds, 55 C for 30 seconds, and 72 C for 60 seconds after the initial 120-second denaturation at 94 C, and the monoplex PCR reactions (for TERT) were cycled 50 times at 94 C for 10 seconds, 70 C for 10 seconds, and 72 C for 60 seconds after the initial 120-second denaturation at 94 C. Primer information is provided in Supplementary Table S1 online.
After thermal cycling, all PCR products were incubated with ExoSap-It (Thermo Fisher Scientific), following the manufacturer's instruction to enzymatically remove unconsumed deoxynucleotides and primers, as well as any other single-stranded DNA present in the PCR products. These cleaned PCR products were then used for Sanger sequencing of individual gene regions in separate tubes, one per gene region, with a nested primer specific to that gene region. Chromatograms from the Sanger sequencing were reviewed, and sequence data from all samples were aligned to a reference sequence with a multisequence alignment analysis software, Sequencher, version 5.4.6 (GeneCodes, Ann Arbor, MI) to determine the presence of mutations (sequence mismatches) in amplicons from each gDNA sample.
Statistical analysis
Statistical analyses were performed using Excel (Microsoft, Redmond, WA) or R (R Core Team, Vienna, Austria) for which the null hypothesis was no difference among procedures or conditions; analyses were also performed with Student t -test. P values of less than 0.05 were considered significant.
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